Cargando…

Rabdomiólisis severa asociada a atorvastatina. Reporte de caso

BACKGROUND: Dyslipidemia is a risk factor for the development of atherosclerosis and ischemic heart disease. Statins are safe drugs that are part of the routine treatment in patients with Acute Myocardial Infarction (AMI), however, rhabdomyolysis associated with severe myonecrosis due to statins can...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina-Romero, Jorge, Toledo-Salinas, Otoniel, Reyes-Álvarez, Francisco Javier, Gómez-Flores, Saira Sanjuana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Mexicano del Seguro Social 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395881/
https://www.ncbi.nlm.nih.gov/pubmed/37207311
_version_ 1785083676876341248
author Medina-Romero, Jorge
Toledo-Salinas, Otoniel
Reyes-Álvarez, Francisco Javier
Gómez-Flores, Saira Sanjuana
author_facet Medina-Romero, Jorge
Toledo-Salinas, Otoniel
Reyes-Álvarez, Francisco Javier
Gómez-Flores, Saira Sanjuana
author_sort Medina-Romero, Jorge
collection PubMed
description BACKGROUND: Dyslipidemia is a risk factor for the development of atherosclerosis and ischemic heart disease. Statins are safe drugs that are part of the routine treatment in patients with Acute Myocardial Infarction (AMI), however, rhabdomyolysis associated with severe myonecrosis due to statins can occur and associated complications such as acute kidney injury increase mortality. The main objective of this article is to report the case of a critically ill patient with AMI who presented severe statin-associated rhabdomyolysis documented with muscle biopsy. CLINICAL CASE: A 54-year-old man who presented with AMI, cardiogenic shock, and cardiorespiratory arrest requiring cardiopulmonary resuscitation, fibrinolysis, and successful salvage coronary angiography. However, he presented severe rhabdomyolysis associated with atorvastatin that required suspension of the drug and multi-organ support in a Coronary Care Unit. CONCLUSIONS: The prevalence of statin-associated rhabdomyolysis is low, however, the late elevation of CPK above 10 times its upper normal value in those patients with successful percutaneous coronary angiography should promptly draw attention, generate a diagnostic approach towards non-traumatic acquired causes of rhabdomyolysis and assess the suspension of statins.
format Online
Article
Text
id pubmed-10395881
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Instituto Mexicano del Seguro Social
record_format MEDLINE/PubMed
spelling pubmed-103958812023-08-04 Rabdomiólisis severa asociada a atorvastatina. Reporte de caso Medina-Romero, Jorge Toledo-Salinas, Otoniel Reyes-Álvarez, Francisco Javier Gómez-Flores, Saira Sanjuana Rev Med Inst Mex Seguro Soc Casos Clínicos BACKGROUND: Dyslipidemia is a risk factor for the development of atherosclerosis and ischemic heart disease. Statins are safe drugs that are part of the routine treatment in patients with Acute Myocardial Infarction (AMI), however, rhabdomyolysis associated with severe myonecrosis due to statins can occur and associated complications such as acute kidney injury increase mortality. The main objective of this article is to report the case of a critically ill patient with AMI who presented severe statin-associated rhabdomyolysis documented with muscle biopsy. CLINICAL CASE: A 54-year-old man who presented with AMI, cardiogenic shock, and cardiorespiratory arrest requiring cardiopulmonary resuscitation, fibrinolysis, and successful salvage coronary angiography. However, he presented severe rhabdomyolysis associated with atorvastatin that required suspension of the drug and multi-organ support in a Coronary Care Unit. CONCLUSIONS: The prevalence of statin-associated rhabdomyolysis is low, however, the late elevation of CPK above 10 times its upper normal value in those patients with successful percutaneous coronary angiography should promptly draw attention, generate a diagnostic approach towards non-traumatic acquired causes of rhabdomyolysis and assess the suspension of statins. Instituto Mexicano del Seguro Social 2023 /pmc/articles/PMC10395881/ /pubmed/37207311 Text en © 2023 Revista Medica del Instituto Mexicano del Seguro Social. https://creativecommons.org/licenses/by-nc-nd/4.0/Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
spellingShingle Casos Clínicos
Medina-Romero, Jorge
Toledo-Salinas, Otoniel
Reyes-Álvarez, Francisco Javier
Gómez-Flores, Saira Sanjuana
Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title_full Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title_fullStr Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title_full_unstemmed Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title_short Rabdomiólisis severa asociada a atorvastatina. Reporte de caso
title_sort rabdomiólisis severa asociada a atorvastatina. reporte de caso
topic Casos Clínicos
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395881/
https://www.ncbi.nlm.nih.gov/pubmed/37207311
work_keys_str_mv AT medinaromerojorge rabdomiolisisseveraasociadaaatorvastatinareportedecaso
AT toledosalinasotoniel rabdomiolisisseveraasociadaaatorvastatinareportedecaso
AT reyesalvarezfranciscojavier rabdomiolisisseveraasociadaaatorvastatinareportedecaso
AT gomezfloressairasanjuana rabdomiolisisseveraasociadaaatorvastatinareportedecaso